Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.855 -3.095 (-1.15%) Market Cap: 34.29 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,063.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc ALN-APP Call Transcript

Apr 26, 2023 / 08:30PM GMT
Release Date Price: $197.52 (-2.29%)
Operator

Hello, and welcome to the Alnylam Pharmaceuticals conference call to discuss interim results from the Phase I study of ALN-APP Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to the company. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good afternoon. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, our Chief Executive Officer; Pushkal Garg, our Chief Medical Officer; and Akshay Vaishnaw, our President. Also in the room and available for Q&A is Kevin Fitzgerald, our Chief Scientific Officer. For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website, alnylam.com/events. Now turning to today's call as outlined on Slide 2. Yvonne will provide some opening remarks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot